-+ 0.00%
-+ 0.00%
-+ 0.00%

RenovoRx ASCO abstract reports PK/PD data from Phase III TIGeR-PaC trial

PUBT·04/23/2026 12:32:08
Listen to the news
RenovoRx ASCO abstract reports PK/PD data from Phase III TIGeR-PaC trial
  • RenovoRx disclosed an abstract from a pharmacokinetic and pharmacodynamic sub-study within its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer was accepted for presentation at 2026 ASCO Annual Meeting.
  • Data have not been presented yet; online abstract publication scheduled for May 21, 2026, with conference presentation during May 29–June 2, 2026.
  • Sub-study evaluates intra-arterial gemcitabine delivered via RenovoCath versus intravenous gemcitabine, aiming to support targeted delivery that reduces systemic exposure while increasing inactive metabolite levels.
  • Analysis also examines whether metabolite levels track with changes in CA 19-9, a commonly used biomarker for chemotherapy response.
  • RenovoRx framed findings as supportive of its TAMP platform strategy to improve tolerability while preserving therapeutic effect, a key differentiator for its drug-device combination program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230830PRIMZONEFULLFEED9695428) on April 23, 2026, and is solely responsible for the information contained therein.